---
title: "Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Limitations of current therapies"
description: "Formulary evidence on Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Limitations of current therapies. Topics: Non-response and incomplete response to available treatments; Long-term dependence on immunoglobulin; No biomarker of ongoing need for treatment, and overtreatment; Relapse after stopping plasma exchange; 2 further topics. 7 evidence topics quoted from 15 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description/limitations-of-current-therapies"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Limitations of current therapies

<a id="heading-2.2.2.1.7"></a>

## 2.2.2.1.7 Limitations of Current Therapies

<a id="topic-2.2.2.1.7-1"></a>

### Summary

Around a third of patients do not respond to currently available treatments, and many patients with a partial response have residual neurological impairment; Sanofi states that, in people with CIDP who respond, about 70% of the response is considered incomplete. Approximately two-thirds of patients need long-term intravenous immunoglobulin, and in a US claims analysis 62% of immunoglobulin users were chronic users during the first year after the index date. Biomarkers of disease activity are lacking: in a withdrawal trial, 41% of participants withdrawn from intravenous immunoglobulin remained stable for 24 weeks, compared with 58% who continued it, and the lack of biomarkers can lead to potential overtreatment. After plasma exchange, 8 of 12 responders relapsed within 7 to 14 days of stopping. About 30% of survey respondents receiving intravenous immunoglobulin missed school or work because of infusions, and subcutaneous immunoglobulin typically requires administration once or twice a week. The Gamunex-C prescribing information carries a boxed warning for thrombosis, renal dysfunction, and acute renal failure, and states that renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur with immune globulin intravenous products in predisposed patients; observational studies indicate that corticosteroids carry a long-term risk of serious side effects.

Source: [Allen et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39304241/); [Sanofi (2026)](https://www.sanofi.com/en/media-room/press-releases/2026/2026-06-10-05-00-00-3309444); [van Schaik et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29122523/); [Blein et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12896209/); [Guptill et al. (2024)](https://www.ispor.org/heor-resources/presentations-database/presentation/intl2024-3895/136957); [Adrichem et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9166547/); [Hahn et al. (1996)](https://pubmed.ncbi.nlm.nih.gov/8813270/); [Allen et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7854453/); [Hadden et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11625974/); [Gamunex-C prescribing information (2026)](https://www.fda.gov/media/70738/download); [Hughes et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6747552/)

<a id="topic-2.2.2.1.7-2"></a>

### Non-response and incomplete response to available treatments

> “Around a third of patients do not respond to currently available treatments, and many patients with a partial response have residual neurological impairment, highlighting the need for effective alternatives.”

Source: [Allen et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39304241/)

> “Approximately 30% of people with CIDP do not respond to standard therapies. In people with CIDP who do respond, about 70% of the response is considered incomplete. Less than one-third of people with CIDP remain in remission without continued therapy.”

Source: [Sanofi (2026)](https://www.sanofi.com/en/media-room/press-releases/2026/2026-06-10-05-00-00-3309444)

> “Some patients were dissatisfied by treatment outcomes (11.0%) and symptom control (12.2%). Overall, mean (SD) patient‐reported scores were 62.1 (20.4) for I‐RODS, 35.0 (11.1) for FACIT fatigue, and 0.662 (0.253) for EQ‐5D‐5L.”
> “Despite the use of guideline treatments, there were unmet needs and a continued disease burden for patients.”

Source: [Querol et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12361836/)

<a id="topic-2.2.2.1.7-3"></a>

### Long-term dependence on immunoglobulin

> “Approximately two-thirds of patients with chronic inflammatory demyelinating polyneuropathy (CIDP) need long-term intravenous immunoglobulin.”

Source: [van Schaik et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29122523/)

> “Of patients who used Ig, 62% ( n = 1,113) were chronic and 38% ( n = 690) were intermittent users during the 1-year post-index.”
> “A substantial proportion of Ig users were chronic users who also received other CIDP therapies, with steroids being most common. This suggests a potentially pronounced burden among patients treated with frequent Ig and steroids.”

Source: [Blein et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12896209/)

> “Over 70% of CIDP patients require ongoing treatment with immunosuppressants such as IVIg, S.C. immune globulin, PLEX or steroids.”

Source: [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)

<a id="topic-2.2.2.1.7-4"></a>

### No biomarker of ongoing need for treatment, and overtreatment

> “Biomarkers for disease activity are lacking, making the need for ongoing treatment difficult to assess, leading to potential overtreatment and high health-care costs.”
> “In the intravenous immunoglobulin withdrawal group, 41% remained stable for 24 weeks, compared to 58% in the intravenous immunoglobulin continuation group (−17%; 95% CI −39 to 8).”
> “Of the intravenous immunoglobulin withdrawal group, 28% remained stable at the end of the extension phase.”

Source: [Adrichem et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9166547/)

> “45/125 individuals met criteria for clinical stability, with median age 58 years, I‐RODS 37/48, MRC‐SS 69/70 and annual treatment costs £107 000/person.”
> “12 of 36 (33.3%) consented to cessation trial and eight of those (66.7%) remained stable off treatment for ≥ 12 months.”

Source: [Koay et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11836592/)

<a id="topic-2.2.2.1.7-5"></a>

### Relapse after stopping plasma exchange

> “Eight of 12 PE responders (66%) relapsed within 7-14 days after stopping PE.”

Source: [Hahn et al. (1996)](https://pubmed.ncbi.nlm.nih.gov/8813270/)

> “Rapid deterioration after plasma exchange occurred in eight of 12 who had improved.”

Source: [Mehndiratta et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6734114/)

<a id="topic-2.2.2.1.7-6"></a>

### Burden of infusions

> “IVIg was associated with venous access issues and work/school absenteeism.”
> “About 30% of respondents in each group that received IVIg missed school or work because of the infusions”

Source: [Allen et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7854453/)

> “SCIG has fewer systemic adverse reactions than IVIG and can be administered at home by patients or caregivers, 8 but typically requires more frequent infusions, such as administration once or twice a week.”
> “Mean (standard deviation) infusion duration was 135.5 (62.8) minutes.”

Source: [Hadden et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11625974/)

<a id="topic-2.2.2.1.7-7"></a>

### Safety limitations of immunoglobulin and corticosteroids

> “WARNING: THROMBOSIS, RENAL DYSFUNCTION and ACUTE RENAL FAILURE”
> “Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur with immune globulin intravenous (IGIV) products in predisposed patients.”

Source: [Gamunex-C prescribing information (2026)](https://www.fda.gov/media/70738/download)

> “We also know from observational studies that corticosteroids carry the long‐term risk of serious side effects.”

Source: [Hughes et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6747552/)

## Related pages
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: References](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references.md)
